Description:
A5397/HVTN 603 is a double-blinded, placebo-controlled study which will give participants 2 injections of a study vaccine called ID93+GLA-SE or a placebo at different times after they have started taking TB treatment. The researchers will compare responses in people who get the study vaccine to people who get the placebo. This study will enroll both people with and without HIV. It is the first to test ID93 + GLA-SE in people living with HIV (PLWH).
Start Date: July 24, 2023
Eligibility:
People aged 18 years or older who have: pulmonary TB that is sensitive to certain TB medications.
Do not have drug resistant TB and have not been treated for TB previously.
Started standard TB treatment (per local guidelines) within the past 7 days and are living with or without HIV.
For PLWH: taking HIV treatment for at least 90 days with an undetectable viral load and a CD4 count at least 250.
To Participate in the study kindly reach us via: